bone mineral density; clinical trial; denosumab; fracture; osteoporosis; safety
Abstract :
[en] Summary: The FREEDOM study and its Extension provide
long-term information about the effects of denosumab for
the treatment of postmenopausal osteoporosis. Treatment for
up to 8 years was associated with persistent reduction of bone
turnover, continued increases in bone mineral density, low
fracture incidence, and a favorable benefit/risk profile.
Introduction: This study aims to report the results through year
5 of the FREEDOM Extension study, representing up to
8 years of continued denosumab treatment in postmenopausal
women with osteoporosis.
Methods : Women who completed the 3-year FREEDOM
study were eligible to enter the 7-year open-label
FREEDOM Extension in which all participants are scheduled
to receive denosumab, since placebo assignment was
discontinued for ethical reasons. A total of 4550 women enrolled
in the Extension (2343 long-term; 2207 cross-over). In
this analysis, women in the long-term and cross-over groups
received denosumab for up to 8 and 5 years, respectively.
Results Throughout the Extension, sustained reduction of
bone turnover markers (BTMs) was observed in both
groups. In the long-term group, mean bone mineral density
(BMD) continued to increase significantly at each
time point measured, for cumulative 8-year gains of 18.4
and 8.3 % at the lumbar spine and total hip, respectively.
In the cross-over group, mean BMD increased significantly
from the Extension baseline for 5-year cumulative
gains of 13.1 and 6.2 % at the lumbar spine and total
hip, respectively. The yearly incidence of new vertebral
and nonvertebral fractures remained low in both groups.
The incidence of adverse and serious adverse events did
not increase over time. Through Extension year 5, eight
events of osteonecrosis of the jaw and two events of atypical
femoral fracture were confirmed.
Disciplines :
General & internal medicine
Author, co-author :
PAPAPOULOS, S.
LIPPUNER, K.
ROUX, C.
LIN, C.J.
KENDLER, D.L.
LEWIECKI, E.M.
BRANDI, M.L.
CZEWINSKI, E.
FRANEK, E.
LAKATOS, P.
MAUTALEN, C.
MINISOLA, S.
Reginster, Jean-Yves ; Université de Liège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765
Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwinski E, Krieg MA et al (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the freedom extension. J Bone Miner Res 27:694–701
Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E, Krieg MA, Mellstrom D et al (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the freedom extension. J Clin Endocrinol Metab 98:4483–4492
Keaveny TM, McClung MR, Genant HK, Zanchetta JR, Kendler D, Brown JP, Goemaere S et al (2014) Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab. J Bone Miner Res 29:158–165
Austin M, Yang YC, Vittinghoff E, Adami S, Boonen S, Bauer DC, Bianchi G et al (2012) Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res 27:687–693
Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR, Reid IR et al (2011) Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 26:530–537
Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–1148
Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the american society for bone and mineral research. J Bone Miner Res 25:2267–2294
Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216–1226
Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA et al (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–1199
Devogelaer JP, Brown JP, Burckhardt P, Meunier PJ, Goemaere S, Lippuner K, Body JJ et al (2007) Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int 18:1211–1218
McClung MR, Lewiecki EM, Geller ML, Bolognese MA, Peacock M, Weinstein RL, Ding B et al (2013) Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int 24:227–235
Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–2938
Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR et al (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27:243–254
Seeman E, Delmas PD, Hanley DA, Sellmeyer D, Cheung AM, Shane E, Kearns A et al (2010) Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 25:1886–1894
Seeman E, Libanati C, Austin M, Chapurlat R, Boyd SK, Zebaze R, Hanley DA et al (2011) The transitory increase in PTH following denosumab administration is associated with reduced intracortical porosity: a distinctive attribute of denosumab therapy. J Bone Miner Res 26(Suppl 1):S22
Ominsky M, Libanati C, Boyce RW, Kostenuik PJ, Baron R, Wagman RB, Dempster DW (2013) Continuous modeling-based bone formation: a novel mechanism that could explain the sustained increases in hip bone mineral density with denosumab treatment. J Bone Miner Res 28(Suppl 1):S504
Epker BN, Frost HM (1966) Periosteal appositional bone growth from age two to age seventy in man. A tetracycline evaluation. Anat Rec 154:573–577
Kontulainen S, Sievanen H, Kannus P, Pasanen M, Vuori I (2002) Effect of long-term impact-loading on mass, size, and estimated strength of humerus and radius of female racquet-sports players: a peripheral quantitative computed tomography study between young and old starters and controls. J Bone Miner Res 17:2281–2289
Ferrari S, Adachi JD, Lippuner K, Zapalowski C, Miller PD, Reginster J-Y, Törring O et al (2015) Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the freedom open-label extension and influence of hip bone mineral density after 3 years. Osteoporos Int (Accepted)
Adachi J, Ho P, Lin C, Bolognese M, Bone H, Hadji P, Papapoulos S et al (2014) Evolution of subject characteristics in freedom and its extension for up to 8 years. J Bone Miner Res 29(Suppl 1):S270
